Antiglaucoma EP 2 Agonists: A Long Road That Led Somewhere

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP agonists from conception to clini...

Full description

Saved in:
Bibliographic Details
Published inJournal of ocular pharmacology and therapeutics Vol. 35; no. 9; p. 469
Main Authors Woodward, David F, Wang, Jenny W, Stamer, W Daniel, Lütjen-Drecoll, E, Krauss, Achim H-P, Toris, Carol B
Format Journal Article
LanguageEnglish
Published United States 01.11.2019
Subjects
glaucoma therapy
EP2 agonists
drug delivery
Online AccessGet more information

Cover

More Information
Summary:For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.
ISSN:1557-7732
DOI:10.1089/jop.2019.0041